Health
SARS-CoV-2 replicon for high-throughput antiviral screening – DocWire News
J Gen Virol. 2021 May;102(5). doi: 10.1099/jgv.0.001583.ABSTRACTThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which is highly
J Gen Virol. 2021 May;102(5). doi: 10.1099/jgv.0.001583.
ABSTRACT
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which is highly pathogenic and classified as a biosafety level 3 (BSL-3) agent, has greatly threatened global health and efficacious antivirals are urgently needed. The high requirement of facilities to manipulate the live virus has limited the development of antiviral study. Here, we constructed a reporter replicon of SARS-CoV-2, which can be handled in a BSL-2…
-
Noosa News17 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business18 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News20 hours ago‘They’re not taking the concerns of women seriously’
-
Business22 hours agoDividends from ASX 200 bank shares ‘looking very stretched’: expert